Lindora

Item 7 of the 2024 FDD pegs total investment at $272,350-$491,750, including a $60,000 franchise fee, with ongoing fees at 7% royalty, 2% brand fund, and a flat $700 monthly technology charge—positioning Lindora mid-pack for wellness services costs but with added tech overhead versus category norms around 6% royalties. Item 19 discloses average gross revenue of $85,309 and median $79,721 across 31 locations, figures that signal modest scale in a high-investment space; at these levels, after fees eating 9%+ plus tech costs, breakeven likely demands tight operations and upselling services like IV therapies or hormones. No SBA default rates are detailed, but the system's youth—franchising barely a year—means limited loan history, urging caution on financing assumptions.

Growth trends show contraction risks tied to parent Xponential's baggage: litigation notes flag claims from former AKT and current Yoga Six franchisees alleging disclosure failures, fraudulent inducement, and unfair practices, potentially spilling over to Lindora's disclosures. With just 31 units mostly in California, expansion projections remain unproven, and low revenues relative to $300K++ startup suggest profitability hinges on volume growth that hasn't materialized yet. For investors eyeing healthcare wellness, Lindora's data screams 'high-risk pioneer'—strong brand in weight management but untested franchise model demands scrutiny of parent stability before committing.